TAG-72 Antibody (6A190): sc-73106

TAG-72 Antibody (6A190) is a mouse monoclonal IgG1 antibody that detects tumor-associated glycoprotein 72 (TAG-72) with broad species reactivity through various applications including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and flow cytometry (FCM). TAG-72 is a high molecular weight glycoprotein predominantly localized to the cytoplasm and cell membrane of malignant cells, playing a crucial role in tumor biology as a marker for cancer diagnosis and prognosis. TAG-72 expression is notably high in 80% of colorectal carcinomas, while being rarely found in normal epithelial tissues and benign conditions, making TAG-72 a valuable target for cancer immunotherapy and diagnostics. Additionally, TAG-72 is significantly expressed in low-grade mucoepidermoid carcinomas and various gynecologic malignancies, including common epithelial ovarian and endometrial carcinomas, while TAG-72 expression in human prostatic adenocarcinomas has been shown to negatively correlate with the Gleason grade of differentiation. TAG-72′s ability to serve as a reliable biomarker across multiple cancer types underscores TAG-72′s importance in clinical settings, particularly for the purification of primary ovarian cancer cells from patient ascites, thereby facilitating further research and therapeutic development. Anti-TAG-72 antibody (6A190) is an essential tool for researchers and clinicians aiming to explore the complexities of cancer biology and improve patient outcomes.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

TAG-72 Antibody (6A190) References:

1. Prognostic value of the glycoprotein TAG-72 in patients with gastric cancer.  |  González Vitores, AM., et al. 2001. Int J Biol Markers. 16: 121-5. PMID: 11471894
2. Differential TAG-72 epitope expression in breast cancer and lymph node metastases: a marker of a more aggressive phenotype.  |  Galietta, A., et al. 2002. Oncol Rep. 9: 135-40. PMID: 11748471
3. Pretargeted radioimmunotherapy (RIT) with a novel anti-TAG-72 fusion protein.  |  Forero-Torres, A., et al. 2005. Cancer Biother Radiopharm. 20: 379-90. PMID: 16114986
4. Complementation of expression of carcinoembryonic antigen and tumor associated glycoprotein-72 (TAG-72) in human colon adenocarcinomas.  |  Simpson, JF., et al. 1991. Int J Biol Markers. 6: 83-90. PMID: 1716293
5. Targeted gene therapy of LS174 T human colon carcinoma by anti-TAG-72 immunoliposomes.  |  Kim, KS., et al. 2008. Cancer Gene Ther. 15: 331-40. PMID: 18309354
6. Serum levels of tumour associated glycoprotein (TAG 72) in patients with gynaecological malignancies.  |  Scambia, G., et al. 1990. Br J Cancer. 62: 147-51. PMID: 2167724
7. Tumor-associated glycoprotein (TAG-72) detected in adenocarcinomas and benign lesions of the stomach.  |  Ohuchi, N., et al. 1986. Int J Cancer. 38: 643-50. PMID: 2429933
8. Immunohistochemical expression of TAG-72 in normal and malignant endometrium: correlation of antigen expression with estrogen receptor and progesterone receptor levels.  |  Soisson, AP., et al. 1989. Am J Obstet Gynecol. 161: 1258-63. PMID: 2589448
9. Immunoreactivity of tumor-associated glycoprotein (TAG-72) in normal, hyperplastic, and neoplastic colon.  |  Listrom, MB., et al. 1989. Hum Pathol. 20: 994-1000. PMID: 2793163
10. Preselection of patients with high TAG-72 antigen expression leads to targeting of 94% of known metastatic tumor sites with monoclonal antibody I-131-CC49.  |  Kostakoglu, L., et al. 1994. Cancer Invest. 12: 551-8. PMID: 7994589

The preferred TAG-72 antibody is TAG-72 Antibody (CC49): sc-20043.